N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up.

@article{Miner2004NacetylcysteineRC,
  title={N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up.},
  author={Steven Edward Stuart Miner and Vladim{\'i}r Dz̆av{\'i}k and Phong Nguyen-Ho and Robert Richardson and Jan L Mitchell and Deborah Atchison and Peter H. Seidelin and P. N. Daly and John Ross and Peter R McLaughlin and Douglas J Ing and Peter Lewycky and Alan W. Barolet and Leonard Schwartz},
  journal={American heart journal},
  year={2004},
  volume={148 4},
  pages={690-5}
}
BACKGROUND Contrast-associated nephropathy (CAN) is associated with increased morbidity and mortality following percutaneous coronary intervention (PCI). N-acetylcysteine (NAC) has been shown to reduce the risk of nephropathy; however, the impact of NAC on long-term clinical outcomes has not been assessed. METHODS This randomized, double-blind, placebo-controlled trial enrolled 180 patients with moderate renal dysfunction undergoing PCI or coronary angiography with a high likelihood of ad hoc… CONTINUE READING
41 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

Similar Papers

Loading similar papers…